ascendis
pharma
receives
orphan
designation
pth
treatment
hypoparathyroidism
europe
copenhagen
denmark
globe
newswire
ascendis
pharma
nasdaq
asnd
biopharmaceutical
company
utilizes
innovative
transcon
technologies
address
unmet
medical
needs
today
announced
european
commission
ec
granted
orphan
designation
transcon
pth
treatment
hypoparathyroidism
hp
transcon
pth
investigational
prodrug
parathyroid
hormone
pth
development
treatment
adult
hp
designed
replace
pth
physiologic
levels
hours
day
address
symptoms
complications
hp
currently
standard
care
hp
calcium
active
vitamin
calcitriol
alfacalcidol
designation
ec
transcon
pth
acknowledges
need
europe
hormone
replacement
therapy
improve
symptoms
complications
quality
life
people
hp
said
dana
pizzuti
ascendis
pharma
senior
vice
president
development
operations
recently
filed
ind
amendment
phase
pathway
trial
transcon
pth
based
feedback
european
regulatory
authorities
submit
european
clinical
trial
applications
later
year
important
steps
underscore
commitment
developing
novel
therapies
address
unmet
medical
needs
improve
peoples
lives
orphan
designation
granted
therapies
aimed
treatment
prevention
diagnosis
disease
chronically
debilitating
affects
five
persons
european
union
eu
satisfactory
therapy
available
medicine
must
also
expected
provide
significant
benefit
affected
condition
orphan
medicines
years
market
exclusivity
receive
marketing
authorization
eu
designation
supports
future
reimbursement
access
new
therapies
certain
conditions
market
exclusivity
pediatric
indications
may
extended
additional
two
years
transcon
pth
granted
orphan
drug
designation
odd
food
drug
administration
june
hypoparathyroidism
hp
hypoparathyroidism
hp
rare
endocrine
disorder
characterized
insufficient
levels
parathyroid
hormone
pth
resulting
low
calcium
elevated
phosphate
levels
blood
hp
affects
approximately
patients
united
states
europe
japan
south
korea
majority
develop
condition
following
damage
accidental
removal
parathyroid
glands
thyroid
surgery
patients
often
experience
decreased
quality
life
short
term
symptoms
include
weakness
severe
muscle
cramps
tetany
abnormal
sensations
tingling
burning
numbness
paresthesia
memory
loss
impaired
judgment
headache
long
term
complex
disorder
increase
risk
major
complications
extraskeletal
calcium
depositions
occurring
within
brain
lens
eye
kidneys
lead
impaired
renal
function
recently
hp
remained
among
hormonal
insufficiency
states
treated
replacement
missing
hormone
standard
care
active
vitamin
analogs
calcium
supplementation
fully
control
disease
may
contribute
risk
renal
disease
result
patients
hp
estimated
greater
risk
renal
disease
compared
healthy
controls
technology
platform
transcon
refers
transient
proprietary
transcon
platform
innovative
technology
create
new
therapies
designed
potentially
optimize
therapeutic
effect
including
efficacy
safety
dosing
frequency
transcon
molecules
three
components
unmodified
parent
drug
inert
carrier
protects
linker
temporarily
binds
two
bound
carrier
inactivates
shields
parent
drug
clearance
injected
body
physiologic
conditions
ph
temperature
initiate
release
active
unmodified
parent
drug
predictable
manner
parent
drug
unmodified
original
mode
action
expected
maintained
transcon
technologies
applied
broadly
protein
peptide
small
molecule
multiple
therapeutic
areas
used
systemically
locally
ascendis
pharma
ascendis
pharma
applying
innovative
platform
technology
build
leading
fully
integrated
biopharma
company
focused
making
meaningful
difference
patients
lives
guided
core
values
patients
science
passion
company
utilizes
technologies
create
new
potentially
therapies
ascendis
pharma
currently
pipeline
three
independent
endocrinology
rare
disease
product
candidates
clinical
development
advancing
oncology
second
therapeutic
area
focus
company
continues
expand
additional
therapeutic
areas
address
unmet
patient
needs
ascendis
headquartered
copenhagen
denmark
additional
offices
heidelberg
berlin
germany
palo
alto
redwood
city
california
information
please
visit
statements
press
release
contains
statements
involve
substantial
risks
uncertainties
statements
statements
historical
facts
included
press
release
regarding
ascendis
future
operations
plans
objectives
management
statements
examples
statements
include
limited
statements
relating
ascendis
plans
begin
phase
pathway
trial
transcon
pth
year
ii
ascendis
ability
apply
platform
technology
build
leading
fully
integrated
biopharma
company
iii
ascendis
product
pipeline
expansion
additional
therapeutic
areas
iv
ascendis
expectations
regarding
ability
utilize
transcon
technologies
create
new
potentially
therapies
ascendis
may
actually
achieve
plans
carry
intentions
meet
expectations
projections
disclosed
statements
place
undue
reliance
statements
actual
results
events
could
differ
materially
plans
intentions
expectations
projections
disclosed
statements
various
important
factors
could
cause
actual
results
events
differ
materially
statements
ascendis
makes
including
following
unforeseen
safety
efficacy
results
oncology
programs
transcon
hgh
transcon
pth
transcon
cnp
development
programs
unforeseen
expenses
related
development
potential
commercialization
oncology
programs
transcon
hgh
transcon
pth
transcon
cnp
development
programs
selling
general
administrative
expenses
research
development
expenses
ascendis
business
generally
delays
development
oncology
programs
transcon
hgh
transcon
pth
transcon
cnp
development
programs
related
manufacturing
regulatory
requirements
speed
patient
recruitment
unforeseen
delays
dependence
third
party
manufacturers
supply
study
drug
planned
clinical
studies
ascendis
ability
obtain
additional
funding
needed
support
business
activities
effects
business
worldwide
pandemic
description
risks
uncertainties
could
cause
actual
results
differ
expressed
statements
well
risks
relating
ascendis
business
general
see
ascendis
prospectus
supplement
filed
july
ascendis
current
future
reports
filed
submitted
securities
exchange
commission
sec
including
annual
report
form
filed
sec
april
statements
reflect
potential
impact
future
collaborations
acquisitions
mergers
dispositions
joint
ventures
investments
ascendis
may
enter
make
ascendis
assume
obligation
update
statements
except
required
law
ascendis
ascendis
pharma
ascendis
pharma
logo
company
logo
transcon
trademarks
owned
ascendis
pharma
group
october
ascendis
pharma
investor
contact
media
contact
patti
bank
ron
rogers
westwicke
partners
ascendis
pharma
rrs
ir
bollerslev
et
al
euro
j
endo
mannstadt
et
al
nature
reviews
ascendis
pharma
hp
patient
experience
research
hadker
n
et
al
endo
pract
powers
j
et
al
j
bone
miner
res
mitchell
dm
et
al
j
clin
endocrinol
metab
underbjerg
l
et
al
j
bone
miner
res
